ライフサイエンスコーパス: flatulence

1 ability to belch, gas bloating and increased flatulence.

2 e microflora and their propensity to produce flatulence.

3 stinal gas, causing undesirable bloating and flatulence.

4 discomfort, abdominal pain, bloating, and/or flatulence.

5 onstipation, diarrhea, nausea, vomiting, and flatulence.

6 isk (RR) 0.59; 95% CI: 0.36-0.97; P = 0.04], flatulence (14% vs 25%; RR: 0.57; 95% CI: 0.35-0.91; P =

7 ng (7.1% vs. 21.4%; P = 0.242) and increased flatulence (7.1% vs. 42.9%; P = 0.018) was lower compare

8 Symptoms included flatulence (86%), abdominal distention or being underwei

9 Of 188 reported AEs, diarrhea, flatulence, abdominal pain/cramping, and constipation we

10 el movements (5-6 times per day), as well as flatulence and abdominal pain.

11 an anaerobic commensal bacteria linked with flatulence and intestinal bowel diseases.

12 en and intolerance symptoms (abdominal pain, flatulence, and diarrhea) were carefully monitored for 8

13 for severity of abdominal pain, bloating and flatulence, and QoL score between prebiotics and placebo

14 bnormalities (AOR, 1.94; 95% CI, 1.27-2.96), flatulence (AOR, 1.43; 95% CI, 1.01-2.01), skin sensatio

15 accharides (RFOs) are mainly responsible for flatulence by taking soybean derived food products.

16 ped to better understand the behavior of the flatulence-causing oligosaccharides in cowpea seeds duri

17 (compared with placebo: 0.32, P = 0.036) and flatulence (compared with placebo: 0.25, P = 0.007) were

18 Only flatulence episodes were reported during the dietary int

19 ewly emerging parasite that causes diarrhea, flatulence, fatigue, and abdominal pain leading to weigh

20 The clinical evolution of flatulence followed similar patterns in the three groups

21 At 5 years, the Dakkak dysphagia score, flatulence, inability to belch, and inability to relieve

22 wer GI tract, with a significant decrease in flatulence, intestinal cramps, loose stools and diarrhea

23 Patients had more feelings of repletion, flatulence, intestinal murmurs, and burping (p < 0.04).

24 Mild flatulence is frequently observed by subjects being fed

25 ised, IBS symptom scores, pain, bloating and flatulence levels, stool frequency, stool consistency, e

26 an score after FMT, 2.80; range, 1.14-4.94), flatulence (mean reduction, 10%; median score before FMT

27 rse events were gastrointestinal (diarrhoea, flatulence, nausea, and constipation) occurring in 16 (1

28 ort, abdominal bloating, abdominal pain, and flatulence on a scale of 1-6.

29 nce of self-reported diarrhea, constipation, flatulence or bloating, frequent stools, mucus in stools

30 oose stools (p < 0.01), bloating (p < 0.05), flatulence (p < 0.01), urgency (p < 0.05) and any sympto

31 ificant within-group reductions in days with flatulence (p < 0.035), incomplete evacuation (p < 0.05)

32 = 0.03) and the proportion of patients with flatulence (p = 0.02).

33 However, flatulence severity was improved by prebiotics at doses

34 = 0.04), while inulin-type fructans worsened flatulence (SMD: 0.85; 95% CI: 0.23, 1.47; P = 0.007).

35 S-LNP subjects have underlying flatulence that is misattributed to lactose intolerance.

36 Flatulence was higher in fiber groups compared to contro

37 strointestinal symptoms, including diarrhea, flatulence, weight loss, abdominal discomfort, and nause

38 Abdominal pain and flatulence were the most common adverse events.

39 s type, nausea, vomiting, abdominal pain and flatulence) were assessed by a self-administered ad-hoc

40 g from the stomach and less gas bloating and flatulence, whereas reflux is reduced to a similar exten

41 ymptoms (abdominal distension, bloating, and flatulence) without increased breath hydrogen, irrespect